We identified ten patients from medical records at Massachusetts General Hospital (MGH) who had surgery between 2004 and 2019 for multiple early stage, spatially distinct, lung adenocarcinomas, with at least one specimen positive for the EGFR mutation by routine clinical genotyping (Table 1, patients 1–10). Here, EGFR is linked to lung adenocarcinoma.